BackgroundWe aimed at investigating the outcomes of female patients with stage IIIB-IV adenocarcinoma of the lung according to EGFR and K-Ras mutational status.MethodsOne hundred and three consecutive female patients genotyped at a single Italian Institution were analyzed. Patients were planned to receive first-line platinum-based chemotherapy (CT) and a salvage treatment with anti-EGFR tyrosine-kinase inhibitors (TKIs) was proposed irrespective of tumor mutational status. EGFR (exons 18¿21) and K-Ras (exon 2, codons 12¿13) mutations were evaluated by real-time PCR and pyrosequencing. The association of mutational status with clinical variables and treatment benefit was investigated by chi-square test and log-rank test.ResultsEGFR and K-Ras mutations were found in 31 (30%) and 13 (15%) cases, respectively. Sixty-six patients received platinum CT: no correlation was observed between EGFR or K-Ras mutational status and response rate (RR) (p¿>¿0.05). However, patients treated with first-line CT harboring EGFR activating mutations experienced a significantly reduced progression-free survival (PFS) in comparison with wild-type ones (4.4 vs. 6.4 months, respectively; HR 0.597, 95%CI 0.287-0.975; p¿=¿0.048). Thirty-nine patients received salvage treatment with erlotinib: EGFR activating mutations were significantly correlated with RR (60% vs. 12.5%; p¿=¿0.004) and PFS (11.4 vs. 4.5 months; HR 0.491, 95%CI 0.216-0.936; p¿=¿0.044). Responses to erlotinib were not reported among women with K-Ras mutant tumors, while 50% of those with wild-type K-Ras achieved an objective remission (p¿=¿0.296). Median PFS (3.5 vs. 8.8 months; HR 0.284, 95%CI 0.015-0.510; p¿=¿0.010) and OS (3.9 vs. 19.8 months; HR 0.158, 95%CI 0.001-0.075; p¿<¿0.001) were significantly shorter among K-Ras mutant patients treated with TKI.ConclusionsIn our population of Caucasian women with advanced lung adenocarcinoma we observed that the presence of EGFR activating mutations correlates with a significant reduction in the benefit from first-line platinum-based CT, emphasizing the importance of an upfront use of anti-EGFR TKIs in this patient subset. K-Ras mutations seem to correlate with a detrimental effect from anti-EGFR TKI, but this finding deserves further investigation.

EGFR and K-Ras mutations in women with lung adenocarcinoma: implications for treatment strategy definition.

BOLDRINI, LAURA;FONTANINI, GABRIELLA;
2014

Abstract

BackgroundWe aimed at investigating the outcomes of female patients with stage IIIB-IV adenocarcinoma of the lung according to EGFR and K-Ras mutational status.MethodsOne hundred and three consecutive female patients genotyped at a single Italian Institution were analyzed. Patients were planned to receive first-line platinum-based chemotherapy (CT) and a salvage treatment with anti-EGFR tyrosine-kinase inhibitors (TKIs) was proposed irrespective of tumor mutational status. EGFR (exons 18¿21) and K-Ras (exon 2, codons 12¿13) mutations were evaluated by real-time PCR and pyrosequencing. The association of mutational status with clinical variables and treatment benefit was investigated by chi-square test and log-rank test.ResultsEGFR and K-Ras mutations were found in 31 (30%) and 13 (15%) cases, respectively. Sixty-six patients received platinum CT: no correlation was observed between EGFR or K-Ras mutational status and response rate (RR) (p¿>¿0.05). However, patients treated with first-line CT harboring EGFR activating mutations experienced a significantly reduced progression-free survival (PFS) in comparison with wild-type ones (4.4 vs. 6.4 months, respectively; HR 0.597, 95%CI 0.287-0.975; p¿=¿0.048). Thirty-nine patients received salvage treatment with erlotinib: EGFR activating mutations were significantly correlated with RR (60% vs. 12.5%; p¿=¿0.004) and PFS (11.4 vs. 4.5 months; HR 0.491, 95%CI 0.216-0.936; p¿=¿0.044). Responses to erlotinib were not reported among women with K-Ras mutant tumors, while 50% of those with wild-type K-Ras achieved an objective remission (p¿=¿0.296). Median PFS (3.5 vs. 8.8 months; HR 0.284, 95%CI 0.015-0.510; p¿=¿0.010) and OS (3.9 vs. 19.8 months; HR 0.158, 95%CI 0.001-0.075; p¿<¿0.001) were significantly shorter among K-Ras mutant patients treated with TKI.ConclusionsIn our population of Caucasian women with advanced lung adenocarcinoma we observed that the presence of EGFR activating mutations correlates with a significant reduction in the benefit from first-line platinum-based CT, emphasizing the importance of an upfront use of anti-EGFR TKIs in this patient subset. K-Ras mutations seem to correlate with a detrimental effect from anti-EGFR TKI, but this finding deserves further investigation.
Rotella, V; Fornaro, L; Vasile, E; Tibaldi, C; Boldrini, Laura; Chella, A; D. Incecco, A; Cirigliano, G; Chioni, A; Lupi, C; Sensi, E; Ginocchi, L; Giovannelli, S; Pennucci, M; Fontanini, Gabriella; Baldini, E.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11568/584467
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 9
social impact